AC Immune SA (ACIU) Stock AnalysisACIUStock AnalysisAC Immune SA

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology. It operates in the Healthcare sector.

AC Immune SA (ACIU) appears to be a good buy right now due to its recent financial turnaround, with a reported net income of $2.4 million in Q2 2026, compared to significant losses in previous quarters. The stock has also received FDA Fast Track designation for its experimental therapy, which could enhance its market position and investor confidence. However, the current RSI is at 44.7, indicating that the stock is nearing oversold territory, and the forward P/E ratio is 11.24, suggesting potential undervaluation. The main risk is the company's high debt-to-equity ratio of 11.66%, which could impact its financial stability if not managed properly.

3 analysts cover ACIU: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.